Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder

NCT07596212 is registered in ClinicalTrials.gov with University of Illinois at Chicago as lead sponsor.

NCT NCT07596212
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07596212 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder
Lead sponsor
University of Illinois at Chicago
Phase
Phase 1/2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 30, 2031
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, early-stage breast cancer, hormone receptor positive breast carcinoma, hypoactive sexual desire disorder